TAVANTA THERAPEUTICS Trademark

Trademark Overview

On Thursday, May 14, 2020, a trademark application was filed for TAVANTA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the TAVANTA THERAPEUTICS trademark a serial number of 88916847. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, July 8, 2024. This trademark is owned by Druggability Technologies Holdings, Ltd. The TAVANTA THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals for treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex
tavanta therapeutics

General Information

Serial Number88916847
Word MarkTAVANTA THERAPEUTICS
Filing DateThursday, May 14, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, July 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 13, 2020

Trademark Statements

Goods and ServicesHousemark for a full line of prescription pharmaceuticals for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals for treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex
NOT AVAILABLE"THERAPEUTICS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 28, 2020
Primary Code005
First Use Anywhere DateTuesday, December 1, 2020
First Use In Commerce DateTuesday, December 1, 2020

Trademark Owner History

Party NameTAVANTA THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressRADNOR, PA 19087
Party NameDruggability Technologies Holdings, Ltd
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressDublin 2
IE
Party NameDruggability Technologies Holdings, Ltd
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressDublin 2
IE

Trademark Events

Event DateEvent Description
Monday, May 18, 2020NEW APPLICATION ENTERED
Thursday, May 28, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 12, 2020ASSIGNED TO EXAMINER
Tuesday, August 18, 2020NON-FINAL ACTION WRITTEN
Tuesday, August 18, 2020NON-FINAL ACTION E-MAILED
Tuesday, August 18, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 8, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 8, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 9, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 10, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 23, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 13, 2020PUBLISHED FOR OPPOSITION
Tuesday, October 13, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 8, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 8, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, June 8, 2021SOU EXTENSION 1 FILED
Tuesday, June 8, 2021SOU EXTENSION 1 GRANTED
Thursday, June 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 8, 2021SOU EXTENSION 2 GRANTED
Wednesday, December 8, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, December 8, 2021SOU EXTENSION 2 FILED
Friday, December 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 8, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, June 8, 2022SOU EXTENSION 3 FILED
Wednesday, June 8, 2022SOU EXTENSION 3 GRANTED
Friday, June 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 8, 2022SOU TEAS EXTENSION RECEIVED
Thursday, December 8, 2022SOU EXTENSION 4 FILED
Friday, December 23, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 23, 2022SOU EXTENSION 4 GRANTED
Saturday, December 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 11, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, June 8, 2023SOU EXTENSION 5 FILED
Monday, July 10, 2023ABANDONMENT - NO USE STATEMENT FILED
Monday, July 10, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Friday, September 8, 2023TEAS PETITION TO REVIVE RECEIVED
Friday, September 8, 2023PETITION TO REVIVE-GRANTED
Friday, September 8, 2023NOTICE OF REVIVAL - E-MAILED
Friday, September 8, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Friday, September 8, 2023NOTICE OF REVIVAL - E-MAILED
Thursday, September 14, 2023SOU EXTENSION 5 GRANTED
Friday, September 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 8, 2023USE AMENDMENT FILED
Friday, December 8, 2023TEAS STATEMENT OF USE RECEIVED
Friday, December 22, 2023SU - NON-FINAL ACTION - WRITTEN
Wednesday, December 13, 2023STATEMENT OF USE PROCESSING COMPLETE
Friday, December 22, 2023NON-FINAL ACTION E-MAILED
Friday, December 22, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 19, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, March 19, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, July 8, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, July 8, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE

Related Keywords

therapeutics tavanta sclerosis cystic fibrosis tuberous complex multiple cancer pharmaceuticals treatment release